Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 08:05 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement
NCT03724084 · National Cancer Institute (NCI) · PHASE1/PHASE2 · terminated · last registry update 2025-06-18 · Acute myeloid leukemia · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Other - Study agent no longer available” | Open Targets' class: logistics resources, study design | Registry record, National Cancer Institute (NCI) |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against TOP2A in acute myeloid leukemia within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-03-30Results posted on the registry: Medical College of Wisconsin, Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen + Cladribine and Cytarabine (CLLDAC) Regimen (NCT03150004)
- 2025-12-01Phase 3 first posted: Sichuan Baili Pharmaceutical Co., Ltd., BL-M11D1 + Cytarabine (NCT07255872)
- 2025-11-03Phase 3 first posted: Stichting Hemato-Oncologie voor Volwassenen Nederland, Bleximenib + Cytarabine (NCT07223814)
- 2025-10-08Phase 3 first posted: Syndax Pharmaceuticals, Revumenib + Placebo (NCT07211958)
- 2025-08-20Phase 3 first posted: Institute of Hematology & Blood Diseases Hospital, China, Daunorubicin/Idarubicin + Cytarabine (NCT07132684)
- 2025-06-05Phase 3 first posted: Kura Oncology, Inc., Ziftomenib + Placebo (NCT07007312)
- 2025-01-14Results posted on the registry: Astellas Pharma Inc, Gilteritinib + Cytarabine (NCT03182244)
- 2024-12-03Phase 3 first posted: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS, High intensity therapies + Low intensity therapies (NCT06713837)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision